X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUVEN LIFE - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUVEN LIFE GLENMARK PHARMA/
SUVEN LIFE
 
P/E (TTM) x 12.0 19.6 61.2% View Chart
P/BV x 3.2 3.6 87.1% View Chart
Dividend Yield % 0.4 1.0 37.0%  

Financials

 GLENMARK PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
SUVEN LIFE
Mar-16
GLENMARK PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs993339 293.4%   
Low Rs729144 505.1%   
Sales per share (Unadj.) Rs325.539.2 829.5%  
Earnings per share (Unadj.) Rs39.37.5 526.6%  
Cash flow per share (Unadj.) Rs48.78.8 554.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.8 28.0%  
Book value per share (Unadj.) Rs159.249.0 324.9%  
Shares outstanding (eoy) m282.17127.28 221.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.66.2 43.0%   
Avg P/E ratio x21.932.4 67.7%  
P/CF ratio (eoy) x17.727.5 64.3%  
Price / Book Value ratio x5.44.9 109.8%  
Dividend payout %5.126.8 19.0%   
Avg Mkt Cap Rs m242,99130,732 790.7%   
No. of employees `00013.01.0 1,359.2%   
Total wages/salary Rs m16,408416 3,940.5%   
Avg. sales/employee Rs Th7,083.95,236.1 135.3%   
Avg. wages/employee Rs Th1,265.4436.5 289.9%   
Avg. net profit/employee Rs Th855.1995.5 85.9%   
INCOME DATA
Net Sales Rs m91,8574,995 1,838.9%  
Other income Rs m374194 193.1%   
Total revenues Rs m92,2305,189 1,777.5%   
Gross profit Rs m20,3671,233 1,652.4%  
Depreciation Rs m2,644167 1,581.2%   
Interest Rs m2,37354 4,378.6%   
Profit before tax Rs m15,7241,205 1,305.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827255 1,500.7%   
Profit after tax Rs m11,088950 1,167.5%  
Gross profit margin %22.224.7 89.9%  
Effective tax rate %24.321.2 115.0%   
Net profit margin %12.119.0 63.5%  
BALANCE SHEET DATA
Current assets Rs m68,7464,986 1,378.8%   
Current liabilities Rs m27,0271,042 2,593.2%   
Net working cap to sales %45.479.0 57.5%  
Current ratio x2.54.8 53.2%  
Inventory Days Days8561 139.4%  
Debtors Days Days9639 244.1%  
Net fixed assets Rs m24,1323,126 772.1%   
Share capital Rs m282127 221.7%   
"Free" reserves Rs m44,6433,717 1,200.9%   
Net worth Rs m44,9256,236 720.4%   
Long term debt Rs m45,363432 10,493.5%   
Total assets Rs m117,6398,079 1,456.1%  
Interest coverage x7.623.2 32.8%   
Debt to equity ratio x1.00.1 1,456.7%  
Sales to assets ratio x0.80.6 126.3%   
Return on assets %11.412.4 92.1%  
Return on equity %24.715.2 162.1%  
Return on capital %19.118.9 101.4%  
Exports to sales %087.5 0.0%   
Imports to sales %012.2 0.0%   
Exports (fob) Rs mNA4,371 0.0%   
Imports (cif) Rs mNA611 0.0%   
Fx inflow Rs m56,1524,666 1,203.3%   
Fx outflow Rs m8,084942 858.1%   
Net fx Rs m48,0683,724 1,290.6%   
CASH FLOW
From Operations Rs m6,574922 713.0%  
From Investments Rs m-7,124-619 1,150.3%  
From Financial Activity Rs m5,432-698 -777.7%  
Net Cashflow Rs m1,992-396 -503.5%  

Share Holding

Indian Promoters % 48.3 63.4 76.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.0 -  
FIIs % 34.4 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 36.5 28.8%  
Shareholders   56,727 37,287 152.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 20, 2018 11:29 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS